Stocks and Investing Stocks and Investing
Fri, March 11, 2022
Thu, March 10, 2022
Wed, March 9, 2022
Tue, March 8, 2022

Paul Matteis Downgraded (BIIB) to Hold and Decreased Target to $223 on, Mar 8th, 2022


Published on 2024-10-27 20:00:26 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $304 to $223 on, Mar 8th, 2022.

Paul has made no other calls on BIIB in the last 4 months.



There are 18 other peers that have a rating on BIIB. Out of the 18 peers that are also analyzing BIIB, 11 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mohit Bansal of "Wells Fargo" Maintained at Hold with Decreased Target to $235 on, Friday, February 4th, 2022
  • Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $244 on, Thursday, January 20th, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $275 on, Thursday, December 23rd, 2021
  • Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
  • Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021
  • Salveen Richter of "Goldman Sachs" Initiated at Hold and Held Target at $271 on, Monday, December 6th, 2021


These are the ratings of the 7 analyists that currently disagree with Paul


  • Brian Abrahams of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $248 on, Thursday, March 3rd, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Monday, February 7th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $330 on, Friday, February 4th, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $290 on, Friday, February 4th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $350 on, Wednesday, December 22nd, 2021